Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?-Reference-Cited by-同舟云学术

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Published:2019-03-26 Issue: Volume:10 Page:
ISSN:1664-2295
Container-title:Frontiers in Neurology
language:
Short-container-title:Front. Neurol.

Author:

Abdelhak Ahmed,Hottenrott Tilman,Morenas-Rodríguez Estrella,Suárez-Calvet Marc,Zettl Uwe K.,Haass Christian,Meuth Sven G.,Rauer Sebastian,Otto Markus,Tumani Hayrettin,Huss André

Publisher

Frontiers Media SA

Subject

Clinical Neurology,Neurology

Reference50 articles.

1. Primary progressive multiple sclerosis: putting together the puzzle;Abdelhak;Front Neurol.,2017

2. Pathological mechanisms in progressive multiple sclerosis;Mahad;Lancet Neurol.,2015

3. Progressive multiple sclerosis: pathology and pathogenesis;Lassmann;Nat Rev Neurol.,2012

4. Mechanisms of white matter damage in multiple sclerosis;Lassmann;Glia.,2014

5. Brain-specific cytoskeletal damage markers in cerebrospinal fluid: is there a common pattern between amyotrophic lateral sclerosis and primary progressive multiple sclerosis?;Abdelhak;Int J Mol Sci.,2015

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum miR-34a-5p, miR-103a-3p, and miR-376a-3p as possible biomarkers of conversion from relapsing-remitting to secondary progressive multiple sclerosis;Neurobiology of Disease;2024-10

2. Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-10

3. Can Selected Parameters of Brain Injury Reflect Neuronal Damage in Smoldering Multiple Sclerosis?;Diagnostics;2024-09-09

4. Fluid biomarkers in multiple sclerosis: from current to future applications;The Lancet Regional Health - Europe;2024-09

5. An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease;Translational Psychiatry;2024-07-24